Proton Pump Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S4538	Pantoprazole sodium	Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21
S5885	Rabeprazole Related Compound E	Rabeprazole Related Compound E (Rabeprazole thioether) is an active metabolite of rabeprazole, which is a proton pump inhibitor.	Stem Cells Int, 2022, 2022:1396735
S5502	Ilaprazole sodium	Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation.	J Virol, 2021, JVI.00190-21
S4665	Rabeprazole sodium	Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors.	J Virol, 2021, JVI.00190-21
S5058	Revaprazan Hydrochloride	Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. This compound reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump.	ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
S1743	Esomeprazole magnesium	Esomeprazole Magnesium(NEXIUM) is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells.
S2222	PF-3716556	PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H⁺,K⁺-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na⁺,K⁺-ATPase, used for the treatment of gastroesophageal reflux disease.
E4878	Lansoprazole sodium	Lansoprazole Sodium, a sodium salt form of Lansoprazole, is an orally active inhibitor of proton pump, preventing the stomach from producing acid. Lansoprazole enhances the expression and transcriptional effectiveness of runt-related transcription factor 2 (Runx2), stimulating osteoprogenitor cell's commitment and differentiation toward their lineage.
E6009	Esomeprazole	Esomeprazole ((S)-Omeprazole, (-)-Omeprazole) is a potent inhibitor of proton pump. It decreases acid production by inhibiting the H+, K+-ATPase enzyme in gastric parietal cells. Esomeprazole displays pharmacokinetic properties that make it more effective than omeprazole and has the potential for use in research of symptomatic gastroesophageal reflux disease.
S5847	Ethacrynate Sodium	Ethacrynate Sodium (ethacrynic acid sodium) is the sodium salt form of ethacrynic acid, which inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
S6438	Ufiprazole	Ufiprazole (Omeprazole sulfide) is an intermediate used in the production of the gastric proton pump inhibitors omeprazole and esomeprazole.
S5608	Pantoprazole sodium hydrate	Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM.	Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x J Virol, 2021, JVI.00190-21